公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2019 | 4(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin | Lin, Ming-Shiu; Hong, Tse-Ming; Chou, Ting-Hung; Yang, Shuenn-Chen; Chung, Wei-Chia; Weng, Chia-Wei; Tsai, Mei-Ling; Cheng, Ting-Jen Rachel; Chen, Jeremy J W; Lee, Te-Chang; Wong, Chi-Huey; Chein, Rong-Jie; PAN-CHYR YANG | European journal of medicinal chemistry | 10 | 9 | |
2018 | The association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Chen, Kun-Chieh; Hsu, Chia-Hung; KANG-YI SU ; Chen, Jeremy J W; HUEI-WEN CHEN ; SUNG-LIANG YU ; Yang, Tsung-Ying; Chang, Gee-Chen | Cancer Research and Treatment | 47 | 45 | |
2022 | The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Chin, Chun-Shih; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Cancer research and treatment | 9 | 6 | |
2022 | Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 0 | 0 | |
2022 | The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 7 | 7 | |
2022 | HLJ1 amplifies endotoxin-induced sepsis severity by promoting IL-12 heterodimerization in macrophages | Luo, Wei-Jia; SUNG-LIANG YU ; Chang, Chia-Ching; Chien, Min-Hui; Chang, Ya-Ling; Liao, Keng-Mao; Lin, Pei-Chun; KUEI-PIN CHUNG ; YA-HUI CHUANG ; Chen, Jeremy J W; PAN-CHYR YANG ; KANG-YI SU | eLife | 7 | 3 | |
2022 | Id2 exerts tumor suppressor properties in lung cancer through its effects on cancer cell invasion and migration | Chen, Jian-Ting; Hsu, Yuan-Ling; Hsu, Yi-Chiung; Tseng, Yi-Hsin; Liu, Ming-Han; Weng, Chia-Wei; Lin, Ching-Hao; SZU-HUA PAN ; Chen, Jeremy J W; Wang, Chi-Chung | Frontiers in Oncology | 3 | 3 | |
2021 | The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M | Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Yang, Tsung-Ying; Chang, Gee-Chen | Scientific reports | 9 | 9 | |
2023 | Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer | Wang, Chi-Liang; Hsu, Kuo-Hsuan; Chang, Ya-Hsuan; CHAO-CHI HO ; CHUN-JU CHIANG ; Chen, Kun-Chieh; Cheung, Yun-Chung; Huang, Pei-Ching; Chen, Yu-Ruei; Chen, Chih-Yi ; Hsu, Chung-Ping; Hsia, Jiun-Yi; Chen, Hsuan-Yu; Yang, Shi-Yi; Li, Yao-Jen; Yang, Tsung-Ying; Tseng, Jeng-Sen; Chuang, Cheng-Yen; Hsiung, Chao A; Chen, Yuh-Min; Huang, Ming-Shyan; CHONG-JEN YU ; KUAN-YU CHEN ; Su, Wu-Chou; Chen, Jeremy J W; SUNG-LIANG YU ; Chen, Chien-Jen; PAN-CHYR YANG ; Tsai, Ying-Huang; Chang, Gee-Chen | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2 | 0 | |
2021 | MITF functions as a tumor suppressor in non-small cell lung cancer beyond the canonically oncogenic role | Hsiao, Yi-Jing; Chang, Wen-Hsin; Chen, Hsuan-Yu; Hsu, Yin-Chen; Chiu, Su-Chin; Chiang, Ching-Cheng; Chang, Gee-Chen; Chen, Yi-Ju; Wang, Chia-Yu; Chen, Yan-Ming; Lin, Chien-Yu; Chen, Yu-Ju; PAN-CHYR YANG ; Chen, Jeremy J W; SUNG-LIANG YU | Aging | 6 | 0 | |
2022 | PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients | Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Huang, Yen-Hsiang; Chang, Gee-Chen | Scientific reports | 11 | 9 | |
2021 | Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients | Hsu, Kuo-Hsuan; Huang, Jing-Wen; Tseng, Jeng-Sen; Chen, Kuan-Wen; Weng, Yih-Chyang; SUNG-LIANG YU ; Yang, Tsung-Ying; Huang, Yen-Hsiang; Chen, Jeremy J W; Chen, Kun-Chieh; Chang, Gee-Chen | OncoTargets and therapy | 6 | 6 | |
2021 | Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M | Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Yang, Tsung-Ying; Chang, Gee-Chen | Scientific reports | 0 | 0 | |